Cover Image
市場調查報告書

生技仿製藥&生物優勝藥抗體的競爭分析

Competitor Analysis: Biosimilar & Biosuperior Therapeutic Antibodies - 2016 Update

出版商 La Merie Publishing 商品編碼 327820
出版日期 內容資訊 英文 462 Pages
訂單完成後即時交付
價格
Back to Top
生技仿製藥&生物優勝藥抗體的競爭分析 Competitor Analysis: Biosimilar & Biosuperior Therapeutic Antibodies - 2016 Update
出版日期: 2016年05月25日 內容資訊: 英文 462 Pages
簡介

本報告提供生技仿製藥及Bio-Superior抗體的最新趨勢調查,提供您各抗體種類的已上市鼻祖(originator)藥物及生技仿製藥&生物優勝藥產品的銷售情況與預測,彙整適應症的組合,開發平台趨勢,企業的開發情形等資料。

抗體的銷售額實際成果

  • 概要:生物製藥的銷售額:各級產品
  • 概要:抗體醫藥品的銷售額:各級產品
  • 重量級抗體醫藥品現況
  • 抗TNF抗體的銷售額實際成果
  • 癌症抗體的銷售額實際成果
  • 其他抗發炎抗體的銷售額實際成果
  • 眼科相關抗體的銷售額實際成果
  • 心代謝&抗感染抗體的銷售額實際成果

生技仿製藥&生物優勝藥抗TNF抗體:最新資料

  • 鼻祖(originator)抗TNF抗體
    • 已通過核准·已上市抗TNF抗體的適應症
    • 銷售額:抗TNF抗體
    • Humira:近幾年已批准開發平台·最新趨勢
    • Remicade:近幾年已批准開發平台·最新趨勢
    • Enbrel:近幾年已批准開發平台·最新趨勢
    • Simponi:近幾年已批准開發平台·最新趨勢
    • Cimzia:近幾年已批准開發平台·最新趨勢
    • 生技仿製藥抗TNF抗體的防衛策略
  • 生物優勝藥抗TNF抗體
    • 非抗體抗TNF生物優勝藥
    • 抗TNF 生物優勝藥抗體
  • 生技仿製藥抗TNF抗體
    • Humira生技仿製藥抗體
    • Enbrel生技仿製藥抗體
    • Remicade生技仿製藥抗體
    • Simponi & Cimzia生技仿製藥抗體

生技仿製藥&生物優勝藥抗VEGF/R抗體:最新資料

  • 癌症領域的已上市抗VEGF/R產品
    • Avastin·Zaltrap·Cyramza的銷售情況
    • Avastin:銷售額·適應症組合
    • Zaltrap:銷售額·適應症組合
    • Cyramza:銷售額·適應症組合
  • 抗VEGF生物優勝藥:Avastin·Zaltrap
    • 癌症領域的開發平台
    • 癌症領域的雙特異性抗VEGF的開發平台
  • 抗VEGF-R生物優勝藥:Cyramza
    • 癌症領域上的反抗VEGF-R生物優勝藥的開發平台
    • 癌症領域的雙特異性抗VEGF-R的開發平台
  • 癌症領域的Avastin·Cyramza生技仿製藥的開發平台
  • 眼科的已上市抗VEGF產品
    • Lucentis&Eylea的銷售情況
    • Lucentis:銷售額·適應症組合
    • Eylea:銷售額·適應症組合
  • Lucentis·Eylea的抗VEGF生物優勝藥
    • 眼科的生物優勝藥抗VEGF
    • 眼科的生物優勝藥雙特異性抗VEGF·抗VEGF並用劑
  • 眼科其他的抗VEGF分子
  • 眼科的Lucentis生技仿製藥
  • E眼科的Eylea生技仿製藥
  • 眼科上的反抗VEGF的of標籤利用

生技仿製藥&生物優勝藥抗Her2抗體:最新資料

  • 抗Her2抗體的銷售額
  • 鼻祖(originator)抗Her2抗體
    • Herceptin:已經過核准和適應症 & 開發平台
    • Perjeta:已經過核准和適應症 & 開發平台
    • Kadcyla:已經過核准和適應症 & 開發平台
  • 生物優勝藥抗Her2抗體
    • 第3代抗Her2抗體
    • 雙特異性抗Her2抗體
    • ADC·免疫毒素·免疫細胞激素·放射性醫藥品
  • 生技仿製藥抗Her2抗體
    • Herceptin生技仿製藥抗體
  • Perjeta生技仿製藥抗體

生技仿製藥&生物優勝藥抗CD20單株抗體:最新資料

  • 銷售額:抗CD20單株抗體
  • 鼻祖(originator)抗CD20單株抗體
    • Rituxan / MabThera:已經過核准和適應症&開發平台
    • Gazyva:已經過核准和適應症·開發平台
    • Arzerra:已經過核准和適應症·研發產品線
    • Zevalin:已經過核准和適應症
  • 生物優勝藥抗CD20單株抗體
    • 3rd Generation抗CD20單株抗體
    • 雙特異性抗CD20單株抗體
    • 抗CD20單株抗體藥物複合體 (ADC)·免疫毒素·免疫細胞激素
  • 生技仿製藥抗CD20單株抗體
    • Rituxan/MabThera生技仿製藥抗體
  • Arzerra生技仿製藥抗體

生技仿製藥&生物優勝藥抗EGF-R抗體:最新資料

  • 銷售額:抗EGF-R抗體
  • 鼻祖(originator)抗EGF-R抗體
    • Erbitux:已經過核准和適應症 & 開發平台
    • Vectibix:已經過核准和適應症 & 開發平台
    • 尼妥珠(Nimotuzumab):已經過核准和適應症 & 開發平台
    • Portrazza:已經過核准和適應症 & 開發平台
  • 生物優勝藥抗EGF-R抗體
    • 第3代抗EGF-R抗體
    • 雙特異性抗EGF-R抗體
    • 抗EGF-R ADC
  • 生技仿製藥抗EGF-R抗體
    • Erbitux生技仿製藥抗體

生技仿製藥抗體的下一波趨勢:最新趨勢

  • Abatacept生技仿製藥抗體
  • Aletuzumab生技仿製藥抗體
  • Denosumab生技仿製藥抗體
  • Eculizumab生技仿製藥抗體
  • Omalizumab生技仿製藥抗體
  • Palivizumab生技仿製藥抗體
  • Tocilizumab生技仿製藥抗體
  • Ustekinumab生技仿製藥抗體
  • 免疫查核點抑制劑抗體的生技仿製藥

生技仿製藥&生物優勝藥抗體醫藥品企業的開發平台

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: LMCA0114

This Competitive Intelligence report about ‘Biosimilar & Biosuperior Therapeutic Antibodies’ updates the competitive landscape of biosimilar therapeutic antibodies as of May 2016. The report evaluates the the first wave of biosimilar recombinant monoclonal antibodies in comparison with the corresponding originator antibodies and biosuperior antibodies against the same target. The report also describes the next wave of potential biosimilar versions of therapeutic antibodies loosing patent protection in the time frame of 2019 - 2023. The report specifically lists for each target the branded products with their 2015 sales and up-side indications in development, as well as biosuperior and biosimilar antibody drug candidates in development.

The report includes a compilation of marketed, approved and currently active projects in research and development of biosimilar and biosuperior therapeutic antibodies against commercially and clinically validated targets relevant for the first wave of biosimilar antibodies (VEGF, TNF, Her2, CD20, EGF-R). Relevant first wave originator therapeutic antibodies are Humira, Enbrel, Remicade, Avastin, Lucentis, Eylea, Herceptin, Rituxan / MabThera and Erbitux. Second generation therapeutic antibodies against these targets such as Symponi, Cimzia, Cyramza, Perjeta, Arrzera are also subject of biosimilar activities.

The report also addresses the slowly emerging second wave of biosimilar antibody activities against originator therapeutic antibodies such as abatacept, alemtuzumab, denosumab, eculizumab, omalizumab, pavilizumab, tocilizumab, and ustekinumab.

Competitor projects are listed in a tabular format providing information on:

  • Drug Codes,
  • Target / Mechanism of Action,
  • Class of Compound,
  • Company,
  • Product Category,
  • Indication,
  • R&D Stage and
  • additional comments with a hyperlink leading to the source of information.

SAMPLE

Blockbuster Therapeutic Antibodies in 2015
(by generic name)

Table of Contents

A) 2015 Sales of Therapeutic Antibodies

  • Overview: 2015 Biologics Sales per Class of Products
  • Overview: 2015 Therapeutic Antibody Sales per Class of Products
  • Blockbuster Therapeutic Antibodies in 2015
  • Anti-TNF Antibody Sales in 2015
  • Cancer Antibody Sales in 2015
  • Other Anti-Inflammatory Antibody Sales in 2015
  • Ophthalmic Antibody Sales in 2015
  • Cardiometabolic & Anti-Infective Antibody Sales in 2015

B) Biosimilar and Biosuperior Anti-TNF Antibodies - 2016 Update

1. Originator Anti-TNF Antibodies

  • Approved and Marketed Indications of anti-TNF Antibodies in Regulated Markets
  • 2015 Sales of Anti-TNF Antibodies
  • Sales of Anti-TNF Antibodies in Q1/2016
  • Humira Pipeline of Recently Approved Indications & Upside Developments
  • Remicade Pipeline of Recent Approvals & Upside Indications
  • Enbrel Pipeline of Upside Indications
  • Simponi Pipeline of Recent Approvals & Upside Indications
  • Cimzia Pipeline of Recent Approvals & Upside Indications
  • Defense Strategies against Biosimilar Anti-TNF Antibodies

2. Biosuperior Anti-TNF Antibodies

  • Non-Antibody Anti-TNF Biosuperiors
  • Anti-TNF Biosuperior Antibodies

3. Biosimimilar Anti-TNF Antibodies

  • Humira Biosimilar Antibodies:
    • Developments in Regulated Markets
    • Developments in Less Regulated Markets
  • Enbrel Biosimilar Antibodies:
    • Developments in Regulated Markets
    • Developments in Less Regulated Markets
  • Remicade Biosimilar Antibodies:
    • Developments in Regulated Markets
    • Developments in Less Regulated Market
  • Simponi & Cimzia Biosimilar Antibodies

C) Biosimilar and Biosuperior Anti-VEGF/-R Antibodies - 2016 Update

1) Marketed Anti-VEGF/R Products in Oncology

  • Avastin, Zaltrap & Cyramza Sales 2008 - 2015
  • Avastin Sales and Indication Portfolio
  • Zaltrap Sales and Indication Portfolio
  • Cyramza Sales and Indication Portfolio

2) Anti-VEGF Biosuperiors of Avastin and Zaltrap

  • Anti-VEGF Biosuperior Pipeline in Oncology
  • Bispecific Anti-VEGF Pipeline in Oncology

3) Anti-VEGF-R Biosuperiors of Cyramza

  • Anti-VEGF-R Biosuperior Pipeline in Oncology
  • Bispecific Anti-VEGF-R Pipeline in Oncology

4) Avastin & Cyramza Biosimilar Pipeline in Oncology

5) Marketed Anti-VEGF Products in Ophthalmology

  • Lucentis & Eylea Sales 2008 - 2015
  • Lucentis Sales & Indication Portfolio
  • Eylea Sales & Indication Portfolio

6) Anti-VEGF Biosuperiors of Lucentis and Eylea

  • Biosuperior Anti-VEGF in Ophthalmology
  • Biosuperior Bispecific Anti-VEGF and Anti-VEGF Combinations in Ophthalmology

7) Other Anti-VEGF Molecules in Ophthalmology

8) Lucentis Biosimilars in Ophthalmology

9) Eylea Biosimilars in Ophthalmology

10) Off-Label Use of Anti-VEGF in Ophthalmology

D) Biosimilar and Biosuperior Anti-Her2 Antibodies - 2016 Update

1. 2015 Anti-Her2 Antibody Sales

2. Originator Anti-Her2 Antibodies

  • Herceptin Approved Indications & Pipeline
  • Perjeta Approved Indications & Pipeline
  • Kadcyla Approved Indications & Pipeline

3. Biosuperior Anti-Her2 Antibodies

  • 3rd Generation Anti-Her2 Antibodies
  • Bispecific Anti-Her2 Antibodies
  • Anti-Her2 Antibody-Drug Conjugates, Immunotoxins, Immunocytokines & Radiopharmaceuticals

4. Biosimilar Anti-Her2 Antibodies

  • Herceptin Biosimilar Antibodies
    • Developments in Regulated Markets
    • Development in Less Regulated Markets

5. Perjeta Biosimilar Antibodies

E) Biosimilar and Biosuperior Anti-CD20 Antibodies - 2016 Update

1. 2015 Sales of Anti-CD20 Antibodies

2. Originator Anti-CD20 Antibodies

  • Rituxan / MabThera Approved Indications & Pipeline
  • Gazyva Approved Indications & Pipeline
  • Arzerra Approved Indications and R&D Pipeline
  • Zevalin Approved Indications

3. Biosuperior Anti-CD20 Antibodies

  • 3rd Generation Anti-CD20 Antibodies
  • Bispecific Anti-CD20 Antibodies
  • Anti-CD20 Antibody-Drug Conjugates, Immunotoxins & Immunocytokines

4. Biosimilar Anti-CD20 Antibodies

  • Rituxan/MabThera Biosimilar Antibodies:
    • Developments in Regulated Markets
    • Developments in Less Regulated Markets

5. Arzerra Biosimilar Antibodies

F) Biosimilar and Biosuperior Anti-EGF-R Antibodies - 2016 Update

1. Sales of Anti-EGF-R Antibodies

2. Originator Anti-EGF-R Antibodies

  • Erbitux Approved Indications & Pipeline
  • Vectibix Approved Indications & Pipeline
  • Nimotuzumab Approved Indications & Pipeline
  • Portrazza Approved Indications & Pipeline

3. Biosuperior Anti-EGF-R Antibodies

  • 3rd Generation Anti-EGF-R Antibodies
  • Bispecific Anti-EGF-R Antibodies
  • Anti-EGF-R Antibody Drug Conjugates

4. Biosimilar Anti-EGF-R Antibodies

  • Erbitux Biosimilar Antibodies:
    • Developments in Regulated Markets
    • Developments in Less Regulated Markets

G) Next Wave of Biosimilar Antibodies - 2016 Update

  • Abatacept Biosimilar Antibodies
  • Aletuzumab Biosimilar Antibodies
  • Denosumab Biosimilar Antibodies
  • Eculizumab Biosimilar Antibodies
  • Omalizumab Biosimilar Antibodies
  • Palivizumab Biosimilar Antibodies
  • Tocilizumab Biosimilar Antibodies
  • Ustekinumab Biosimilar Antibodies
  • Biosimilars of Immune Checkpoint Inhibitor Antibodies

H) Corporate Biosimilar & Biosuperior Therapeutic Antibody Pipelines

Compenies mentioned:

  • 3SBio (Shenyang Sunshine Pharmaceutical Co)
  • AbbVie
  • AbClon
  • Ablynx
  • AET Biotech
  • Affibody
  • Affilogic
  • Affimed Therapeutics
  • Affitech
  • Allergan
  • Alopexx Oncology
  • Alteogen
  • Alvogen
  • Ambrx
  • Amega Biotech
  • Amgen
  • AngioChem
  • Apexigen
  • Aprogen
  • Archemix
  • AREVA Med
  • Aryogen
  • Ascendis Pharma
  • AstraZeneca (MedImmune)
  • Avaxia Biologics
  • AVEO Pharmaceuticals
  • Axxo
  • Baliopharm
  • Baxalta
  • Bayer
  • Binex
  • Bio Farma
  • biOasis Technologies
  • Biocad
  • BioCND
  • Biocon
  • Bioeq
  • Biogen
  • Bionovis
  • BioXpress Therapeutics
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Celgene
  • Celltrion
  • Centrose
  • Ceres Oncology
  • Chengdu Kanghong Biotech Co.
  • CIMAB
  • Cipla
  • Clearside Biomedical
  • Coherus Biosciences
  • Complix
  • Cristalia
  • Curaxys
  • CytomX Therapeutics
  • Daewoong Pharmaceutical Co
  • Daiichi Sankyo
  • Delenex Therapeutics
  • Dermira
  • Dong-A ST
  • Dr Reddy's Laboratories
  • Eddingpharma
  • Eisai
  • Eli Lilly
  • EnGenlC
  • Epirus Biopharmaceuticals
  • Esperance Pharmaceuticals
  • Exicure
  • Ferring Pharmaceuticals
  • ForSight VISION4
  • Fosun Pharma
  • Fujifilm Kyowa Kirin Biologics
  • Gansu Duyiwei Biological Pharmaceutical Co
  • Gedeon Richter
  • Gene Techno Science (GTS)
  • GenIlac
  • Genor Biopharma
  • Glenmark Pharmaceuticals
  • Gliknik
  • Glycotope
  • Green Cross
  • Halozyme
  • HanAll Pharmaceuticals
  • Hanwha Chemical Biologics Business
  • Harvest Moon Pharmaceuticals
  • Helvetic BioPharma
  • Hetero Group
  • Hyprocell
  • IBC Generium
  • Ildong Pharmaceutical
  • Immune Pharmaceuticals
  • ImmuneXcite
  • Immunomedics
  • Innogene Kalbiotech
  • Innokeys
  • Innovent Biologics
  • Intas Pharmaceuticals
  • Janssen (Johnson & Johnson)
  • JHL Biotech
  • Jiangsu Simcere Pharmaceutical
  • Jiangsu T-mab Biopharma
  • Kissei Pharmaceutical
  • Kyowa Hakko Kirin
  • LegoChem
  • LG Life Sciences
  • Libbs Farmaceutica
  • Mabion
  • MabTech
  • MabXience
  • MacroGenics
  • Meiji Seika
  • Merck (MSD)
  • Merck Biopharma & HealthCare Biosimilars
  • Merrimack Pharmaceuticals
  • Mersana Therapeutics
  • Merus
  • Mitsubishi Tanabe Pharma
  • Mochida
  • Molecular Partners
  • Molecular Templates
  • Momenta Pharmaceuticals
  • Mundipharm
  • Mycenax Biotech
  • Mylan Pharmaceuticals
  • Nanogen Biopharmaceutical Co
  • Natco Pharma
  • Neurotech
  • Nichi-iko Pharmaceutical
  • Nippon Kayaku
  • Novartis (& Sandoz/Alcon)
  • Oncobiologics
  • OncoMed Pharmaceuticals
  • Ophthea
  • Ophthotech
  • Orygen Biotecnologia
  • PanOptica
  • Paras Biopharmaceuticals
  • Pfenex
  • Pfizer (& Hospira)
  • PharmAbcine
  • Pharmamar
  • Pharmapraxis
  • Pieris Pharmaceuticals
  • PlantForm
  • Polpharma Group
  • Probiomed
  • Protalix Biotherapeutics
  • Ranbaxy
  • Regeneron Pharmaceuticals
  • Reliance Life Sciences
  • Roche
  • Samsung Bioepis (JV of Samsung and Biogen)
  • Sanofi
  • Senju Pharmaceutical
  • Shanghai Biomabs Pharmaceutical
  • Shanghai Celgen BioPharmaceutical Co
  • Shanghai Citi Pacific (CO) Guojian Pharmaceutical Co (CPGP)
  • Shanghai Fudan-Zhangjiang BioPharmaceuticals
  • Shanghai Henlius Biotech
  • Shanghai Zhangjiang Biotechnology (ZJ-Bio)
  • Sirnaomics
  • Sorrento Biologics/Therapeutics
  • Spectrum Pharmaceuticals
  • Stada Arzneimittel
  • STC Biologics
  • Syd labs
  • Symphogen
  • Synthon Biopharmaceuticals
  • Taisho Pharmaceutical
  • Takeda Pharmaceutical Co
  • TG Therapeutics
  • Therapeutics Protein International (TPI)
  • Tillots Pharma
  • Torrent Pharma
  • TPG Biologics
  • Trimer Biotech
  • Triphase Accelerator
  • TSH Pharma
  • Tyrogenex
  • UCB
  • Unum Therapeutics
  • Vaccinex
  • Valeant Pharmaceuticals
  • Valor Biotherapeutics
  • Wuhan YZY Biopharma
  • Xbrane Biopharma
  • Xencor
  • YL Biologics
  • Yuhan
  • Zhejiang Huahai Pharmaceutical Co
  • Zhejiang Medicine
  • Zova Biotherapeutics
  • Zydus Cadila
  • Zymeworks
  • Zyngenia
Back to Top